Evaluation of the safety and efficacy of sorafenib therapy after TACE for unresectable hepatocellular carcinoma (multicenter study).

Trial Profile

Evaluation of the safety and efficacy of sorafenib therapy after TACE for unresectable hepatocellular carcinoma (multicenter study).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Oct 2012

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms i-STEP
  • Most Recent Events

    • 15 Oct 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
    • 14 Oct 2011 Additional lead trial investigator identified as reported by University Hospital Medical Information Network - Japan.
    • 06 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top